Biogen and Dayra Partner to Advance Oral Macrocyclic Therapies

Biogen Inc, a top global biotechnology firm, and Dayra Therapeutics, a leader in the creation of oral macrocyclic peptide treatments for various human illnesses, revealed a research partnership aimed at discovering and developing oral macrocyclic peptides for key targets in immunological diseases.

Macrocyclic peptides exhibit a distinct profile that may provide biologic-like effectiveness and safety in an oral delivery system, potentially challenging existing antibody-based therapies. The partnership strengthens Biogen’s approach to developing a unique immunology portfolio.

Also Read: Abbott Issues Correction for Faulty FreeStyle Libre 3 Sensors

Oral macrocyclic peptides may provide biologic-like effectiveness and safety in a user-friendly oral form. Oral macrocyclic peptides represent a promising category of drugs that can be taken orally and possess the ability for greater specificity, targeting protein binding sites that are difficult for conventional small molecule medications.

Biogen and Dayra will work together to discover, confirm, and enhance oral macrocycle candidates aimed at key immunological targets, while Biogen will take the molecules forward in further development and possible commercialization, including production.

Collaboration enhances Biogen’s immunology approach by expanding its early-stage portfolio and integrating another clinically validated method into its growing immunology strengths.

“With this collaboration, we are adding another potential best-in-class approach to our early-stage portfolio to target multiple high-value immunological conditions,” said Jane Grogan, executive vice president and head of research at Biogen. “Building on multiple technical advances in the field, we believe Dayra Therapeutics’ state-of-the-art macrocycle discovery platform could help realize the full potential of macrocycle-based treatments.”